hims wegovy - Search News

News

Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers

The Motley Fool on MSN · 4h

Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's goal to lead the weight loss market.

CBS News on MSN · 22h

Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Reuters on MSN · 19h

Novo, Hims & Hers engage in war of words after Wegovy deal falls apart

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%. The companies,

14hon MSN

Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

19h

Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

1h

Hims & Hers Health: Significant Impact Of Partnership Termination With Novo Nordisk; Initiate With 'Sell'

Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC ...

23hon MSN

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug

Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the ...

StockStory.org on MSN23h

Hims & Hers Health (HIMS) Stock Trades Down, Here Is Why

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo Nordisk, the maker ...

Zacks Investment Research on MSN4d

Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results